6505NCM216892: INMAZEB INJECTION.
The INMAZEB INJECTION is a the manufacturer industrial component. Key specifications include part_name_assigned_by_controlling_agency: INMAZEB INJECTION SOLUTION, VIAL. This part is cataloged in the U.S.
Government catalog under NSN 6505-01-693-8769, indicating validated use in U.S. government and defense logistics supply chains. Available through authorized enterprise resellers and TPM (Third Party Maintenance) channels.
Verify compatibility with your specific system configuration before ordering.
| part_name_assigned_by_controlling_agency | INMAZEB INJECTION SOLUTION, VIAL |
| NSN | 6505-01-693-8769 |
| SPECIAL FEATURES | ATOLTIVIMAB, MAFTIVIMAB,AND ODESIVIMAB EBGN) INJECTION 241.7 MG / 241.7 MG / 241.7 MG PER 14.5 ML. SINGLE DOSE VIAL. INDICATED FOR THE TREATMENT OF INFECTION CAUSED BY ZAIRE EBOLAVIRUS IN ADULT AND PEDIATRIC PATIENTS, INCLUDING NEONATES; TREATMENT IS MOST EFFECTIVE WHEN GIVEN EARLY IN THE COURSE OF THE DISEASE; INMAZEB (ATOLTIVIMAB, MAFTIVIMAB & ODESIVIMAB-EBGN) IS A NOVEL ANTIBODY MEDICINE; INMAZEB IS ADMINISTERED AS A SINGLE, WEIGHT BASED INTRAVENOUS INFUSION; REFRIGERATE AT 2 TO 8 DEGREES CELSIUS( 36F TO 46F) IN THE ORIGINAL CARTON TO PROTECT FROM LIGHT; DO NOT FREEZE OR SHAKE; DOES NOT CONTAIN PRESERVATIVES; SINGLE DOSE VIAL. |
| PART NAME ASSIGNED BY CONTROLLING AGENCY | INMAZEB INJECTION SOLUTION, VIAL |